Cited by 1,858HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancerBreast Cancer Treatment Studies

The DOI matches its Crossref record; 65 of the 70 references it cites were found in a registry or an index.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Open access

Nagata, Yoichi, Lan, Keng-Hsueh, Zhou, Xiaoyan, Tan, Ming, Esteva, Francisco J., Sahin, Aysegul A., Klos, Kristine S., Li, Ping, Monia, Brett P., Nguyen, Nina T., Hortobagyi, Gabriel N., Hung, Mien-Chie, Yu, Dihua·2004·Cancer Cell

DOI 10.1016/j.ccr.2004.06.022

Open this paper in CoChat — free account Open PDF

Abstract

The ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable therapeutic efficacy in certain patients with ErbB2-overexpressing tumors. The overall trastuzumab response rate, however, is limited and what determines trastuzumab response is poorly understood. Here we report that PTEN activation contributes to trastuzumab's antitumor activity. Trastuzumab treatment quickly increased PTEN membrane localization and phosphatase activity by reducing PTEN tyrosine phosphorylation via Src inhibition. Reducing PTEN in breast cancer cells by antisense oligonucleotides conferred trastuzumab resistance in vitro and in vivo. Patients with PTEN-deficient breast cancers had significantly poorer responses to trastuzumab-based therapy than those with normal PTEN. Thus, PTEN deficiency is a powerful predictor for trastuzumab resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2004.06.022

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,018
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,637
The Multiple Roles of PTEN in Tumor Suppression
Di Cristofano, A., & Pandolfi, P. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80674-1 · Cited by 1,182
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886

Flagged first, then by citations

Show all 70 references

5 of the 70 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Petit, 1997, Neutralizing antibodies against epidermal growth factor and ErbB2/neu receptor tyrosine kinase down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo, Am. J. Pathol., 151, 1523

Sorted by citations

Items 601–700 of 1,001

Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines
Crawford, A. C., & Nahta, R. (2011) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/187569211796957584 · Cited by 55
Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition
Dokmanovic, M., Wu, Y., Shen, Y., Chen, J., Hirsch, D. S., & Wu, W. J. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29171 · Cited by 55
Formation of the eIF4F Translation–Initiation Complex Determines Sensitivity to Anticancer Drugs Targeting the EGFR and HER2 Receptors
Zindy, P. J., Bergé, Y., Allal, B., Filleron, T., Pierredon, S., Cammas, A., Beck, S., Mhamdi, L., Li, F., Favre, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0420 · Cited by 55
Lapatinib Activity in Premalignant Lesions and HER-2–Positive Cancer of the Breast in a Randomized, Placebo-Controlled Presurgical Trial
DeCensi, A., Puntoni, M., Pruneri, G., Guerrieri‐Gonzaga, A., Lazzeroni, M., Serrano, D., Macis, D., Johansson, H. A., Pala, O., Luini, A., et al. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0337 · Cited by 55
Acquisition of chromosome instability is a mechanism to evade oncogene addiction
Salgueiro, L., Buccitelli, C., Rowald, K., Somogyi, K., Kandala, S., Korbel, J. O., & Sotillo, R. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910941 · Cited by 58
Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance
Russo, R. I. C., Béguelin, W., Flaqué, M. C. D., Proietti, C. J., Venturutti, L., Galigniana, N. M., Tkach, M., Guzmán, P., Roa, J. C., O’Brien, N. A., et al. (2014) · Oncogene · doi:10.1038/onc.2014.272 · Cited by 54
Resistance to human epidermal growth factor receptor type 2-targeted therapies
Théry, J., Spano, J., Azria, D., Raymond, É., & Penault-Llorca, F. M. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.01.003 · Cited by 54
When Tumor Suppressor TGFβ Meets the HER2 (ERBB2) Oncogene
Chow, A. Y., Arteaga, C. L., & Wang, S. E. (2011) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-011-9206-4 · Cited by 56
Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
Scaltriti, M., Serra, V., Normant, E., Guzmán, M., Rodríguez, O., Lim, A. R., Slocum, K. L., West, K. A., Rodriguez, V., Prudkin, L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0966 · Cited by 54
Biomarkers of drugs targeting HER ‐family signalling in cancer
Montemurro, F., & Scaltriti, M. (2013) · The Journal of Pathology · doi:10.1002/path.4269 · Cited by 56
PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition
Brady, S. W., Zhang, J., Tsai, M.-H., & Yu, D. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2014.1002693 · Cited by 54
Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions
Ocaña, A., & Amir, E. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.08.001 · Cited by 56
ERK 1/2 Activation Mediates the Neuroprotective Effect of BpV(pic) in Focal Cerebral Ischemia–Reperfusion Injury
Liu, R., Tang, J., Pan, M., Zhuang, Y., Zhang, Y., Liao, H., Zhao, D., Lei, Y., Lei, R.-X., Wang, S., et al. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2558-z · Cited by 54
The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance
Zhang, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107677 · Cited by 56
Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression
Mukohara, T., Shimada, H., Ogasawara, N., Wanikawa, R., Shimomura, M., Nakatsura, T., Ishii, G., Park, J. O., Janne, P. A., Saijo, N., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.056 · Cited by 54
A Bifunctional Targeted Peptide that Blocks HER-2 Tyrosine Kinase and Disables Mitochondrial Function in HER-2-Positive Carcinoma Cells
Fantin, V. R., Berardi, M. J., Babbe, H., Ventosa-Michelman, M., Manning, C. M., & Leder, P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0395 · Cited by 54
The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis
Wang, Y., Liu, Y., Du, Y., Yin, W., & Lu, J. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.794775 · Cited by 53
Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review)
Shimoyama, S. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.218 · Cited by 53
Novel Inhibitors of AKT: Assessment of a Different Approach Targeting the Pleckstrin Homology Domain
Meuillet, E. J. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796011292 · Cited by 52
Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells
Mao, Y., Zhang, Y., Qu, Q., Zhao, M., Lou, Y., Liu, J., Huang, O., Chen, X., Wu, J., & Shen, K. (2015) · Molecular BioSystems · doi:10.1039/c4mb00710g · Cited by 53
Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance
Raja, S. M., Luan, H., Naramura, M., Bailey, T., Clubb, R. J., Band, V., & Band, H. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.90442 · Cited by 53
Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms
Wu, H., Cao, Y., Weng, D., Xing, H., Song, X., Zhou, J., Xu, G., Lu, Y., Wang, S., & Ma, D. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.06.012 · Cited by 53
Protein Kinase A Activation Confers Resistance to Trastuzumab in Human Breast Cancer Cell Lines
Gu, L., Lau, S. K., Loera, S., Somlo, G., & Kane, S. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0585 · Cited by 53
PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells
Merlin (2009) · Oncology Reports · doi:10.3892/or_00000278 · Cited by 53
Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer
Shah, M. A., Kang, Y., Thuss-Patience, P. C., Ohtsu, A., Ajani, J. A., Cutsem, E. V., Hoersch, S., Harle-Yge, M.-L., & de Haas, S. L. (2019) · Gastric Cancer · doi:10.1007/s10120-018-00923-7 · Cited by 53
Phosphatase and Tensin Homologue Deleted on Chromosome 10 Deficiency Accelerates Tumor Induction in a Mouse Model of ErbB-2 Mammary Tumorigenesis
Dourdin, N., Schade, B., Lesurf, R., Hallett, M. T., Munn, R. J., Cardiff, R. D., & Muller, W. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5727 · Cited by 55
Trastuzumab in the management of early and advanced stage breast cancer.
Bartsch, R., Wenzel, C., & Steger, G. G. (2007) · PubMed Central · Cited by 52
Elevated PI3K signaling drives multiple Breast Cancer subtypes
Adams, J. R., Schachter, N. F., Liu, J. C., Zacksenhaus, E., & Egan, S. E. (2011) · Oncotarget · doi:10.18632/oncotarget.285 · Cited by 51
Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers
Lønning, P. E., & Knappskog, S. (2013) · Oncogene · doi:10.1038/onc.2013.48 · Cited by 54
Difference in expression of EGFR, pAkt, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma
Won, H. S., Jung, C. K., Chun, S. H., Kang, J.-H., Kim, Y., Sun, D., & Kim, M. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.04.013 · Cited by 52
MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition
Astanehe, A., Finkbeiner, M., Krzywinski, M. I., Fotovati, A., Dhillon, J., Berquin, I. M., Mills, G. B., Marra, M. A., & Dunn, S. E. (2012) · Oncogene · doi:10.1038/onc.2011.617 · Cited by 52
Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer
LI, D.-C., Zhang, Y., Xie, Y., Xiang, J., Zhu, Y., & Yang, J. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.14 · Cited by 52
Temporal Profiling of Lapatinib-suppressed Phosphorylation Signals in EGFR/HER2 Pathways
Imami, K., Sugiyama, N., Imamura, H., Wakabayashi, M., Tomita, M., Taniguchi, M., Ueno, T., Toi, M., & Ishihama, Y. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.019919 · Cited by 52
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
Wisinski, K. B., Tevaarwerk, A. J., Burkard, M. E., Rampurwala, M. M., Eickhoff, J. C., Bell, M. C., Kolesar, J., Flynn, C. M., & Liu, G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2365 · Cited by 52
Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer
Mehta, G., Parker, J. S., Silva, G. O., Hoadley, K. A., Perou, C. M., & Gatza, M. L. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4139-2 · Cited by 54
Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition
Gale, M., Li, Y., Cao, J. P., Liu, Z. Z., Holmbeck, M. A., Zhang, M., Lang, S. M., Wu, L., DoCarmo, M., Gupta, S., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3985 · Cited by 51
Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment
Hubalek, M., Brunner, C., Matthä, K., & Marth, C. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0838-6 · Cited by 51
Theranostic profiling for actionable aberrations in advanced high risk osteosarcoma with aggressive biology reveals high molecular diversity: the human fingerprint hypothesis
Egas-Bejar, D., Anderson, P. M., Agarwal, R., Corrales‐Medina, F. F., Devarajan, E., Huh, W. W., Brown, R. E., & Subbiah, V. (2014) · Oncoscience · doi:10.18632/oncoscience.21 · Cited by 51
Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer
Kulkarni, S., Reddy, K. B., Esteva, F. J., Moore, H. C. F., Budd, G. T., & Tubbs, R. R. (2009) · Oncogene · doi:10.1038/onc.2009.422 · Cited by 55
Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer
Emde, A., Köstler, W. J., & Yarden, Y. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.09.002 · Cited by 52
Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors
Faversani, A., Vaira, V., Moro, G. P., Tosi, D., Lopergolo, A., Schultz, D., Rivadeneira, D. B., Altieri, D. C., & Bòsari, S. (2014) · Breast Cancer Research · doi:10.1186/bcr3666 · Cited by 52
Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers
Wetterskog, D., Shiu, K.-K., Chong, I. Y.-S., Meijer, T. G., Mackay, A. G., Lambros, M. B. K., Cunningham, D., Reis-Filho, J. S., Lord, C. J., & Ashworth, A. (2013) · Oncogene · doi:10.1038/onc.2013.41 · Cited by 51
FOXO1A Is a Target for HER2-Overexpressing Breast Tumors
Wu, Y., Shang, X., Sarkissyan, M., Slamon, D. J., & Vadgama, J. V. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0176 · Cited by 51
Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast Cancer
Zambrano, J. N., & Yeh, E. S. (2016) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s32791 · Cited by 50
Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies
Singer, C. F., Köstler, W. J., & Hudelist, G. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.02.003 · Cited by 51
The Neuregulin Family of Genes and their Multiple Splice Variants in Breast Cancer
Hayes, N. V. L., & Gullick, W. J. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9078-4 · Cited by 51
HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
Tracey, N., Creedon, H., Kemp, A. J., Culley, J., Muir, M., Klinowska, T. C. M., & Brunton, V. G. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05489-1 · Cited by 50
Successes and Limitations of Targeted Cancer Therapy in Breast Cancer
Curigliano, G., & Criscitiello, C. (2014) · Progress in tumor research · doi:10.1159/000355896 · Cited by 51
Darpp-32 and Its Truncated Variant t-Darpp Have Antagonistic Effects on Breast Cancer Cell Growth and Herceptin Resistance
Gu, L., Waliany, S., & Kane, S. E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006220 · Cited by 50
Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis
Templeton, A. J., Díez-González, L., Ace, O., Vera-Badillo, F., Šeruga, B., Jordán, J., Amir, E., Pandiella, A., & Ocaña, A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.08.003 · Cited by 51
Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance
Gayle, S. S., Arnold, S. L. M., O'Regan, R. M., & Nahta, R. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012799015002 · Cited by 50
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
Wilken, J. A., Webster, K. T., & Maihle, N. J. (2010) · Journal of Ovarian Research · doi:10.1186/1757-2215-3-7 · Cited by 50
Pharmacogenetics and Pharmacogenomics in Oncology Therapeutic Antibody Development
Li, Y., & Beckman, R. A. (2005) · BioTechniques · doi:10.2144/000112043 · Cited by 52
Differential Roles of Phosphoinositide-Dependent Protein Kinase-1 and Akt1 Expression and Phosphorylation in Breast Cancer Cell Resistance to Paclitaxel, Doxorubicin, and Gemcitabine
Liang, K., Lü, Y., Li, X., Zeng, X., Glazer, R. I., Mills, G. B., & Fan, Z. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.023333 · Cited by 50
Physical Intimacy of Breast Cancer Cells with Mesenchymal Stem Cells Elicits Trastuzumab Resistance through Src Activation
Daverey, A., Drain, A. P., & Kidambi, S. (2015) · Scientific Reports · doi:10.1038/srep13744 · Cited by 50
ERBB oncogene proteins as targets for monoclonal antibodies
Polanovsky, O. L., Lebedenko, E. N., & Deyev, S. M. (2012) · Biochemistry (Moscow) · doi:10.1134/s0006297912030029 · Cited by 49
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib
Valabrega, G., Capellero, S., Cavalloni, G., Zaccarello, G., Petrelli, A., Migliardi, G., Milani, A., Neia, C. P., Gammaitoni, L., Sapino, A., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1281-5 · Cited by 50
Prognostic but not predictive role of platelet‐derived growth factor receptors in patients with recurrent glioblastoma
Paulsson, J., Lindh, M. B., Jarvius, M., Puputti, M., Nistér, M., Nupponen, N. N., Paulus, W., Söderberg, O., Dresemann, G. P., von Deimling, A., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25528 · Cited by 49
Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer
Köstler, W. J., Hudelist, G., Rabitsch, W., Czerwenka, K. F., Müller, R., Singer, C. F., & Zielinski, C. C. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-005-0038-8 · Cited by 49
PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2+ breast cancer cells by inducing Bim
Park, S. H., Ito, K., Olcott, W., Katsyv, I., Halstead-Nussloch, G., & Irie, H. Y. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0594-z · Cited by 49
HER-2-positive metastatic breast cancer: trastuzumab and beyond
Metro, G., Mottolese, M., & Fabi, A. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.15.2583 · Cited by 49
Role of Phosphatidylinositol 3,4,5-Trisphosphate in Cell Signaling
Riehle, R. D., Cornea, S., & Degterev, A. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-6331-9_7 · Cited by 49
CDK4/6 inhibitors in HER2-positive breast cancer
Corona, S. P., Ravelli, A., Cretella, D., Cappelletti, M. R., Zanotti, L., Dester, M., Gobbi, A., Petronini, P. G., & Generali, D. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.022 · Cited by 50
Regulation of the tumor suppressor PTEN by natural anticancer compounds
Kim, D., Suh, J., Surh, Y., & Na, H. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13422 · Cited by 48
A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action
Zhang, X., Chen, J., Weng, Z., Li, Q., Zhao, L., Yu, N., Deng, L., Xu, W., Yang, Y., Zhu, Z., et al. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.01.009 · Cited by 49
HER2-Positive Breast Cancer: From Trastuzumab to Innovatory Anti-HER2 Strategies
Whenham, N., D’Hondt, V., & Piccart, M. J. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.002 · Cited by 49
The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what’s genetics got to do with it?
Shelton, J. G., Steelman, L. S., Abrams, S. L., Bertrand, F. E., Franklin, R. A., McMahon, M., & McCubrey, J. A. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.5.1009 · Cited by 49
Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH
Kirkegaard, T., Witton, C. J., Edwards, J., Nielsen, K. V., Jensen, L., Campbell, F., Cooke, T. G., & Bartlett, J. M. S. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03467.x · Cited by 48
HB‐EGF orchestrates the complex signals involved in triple‐negative and trastuzumab‐resistant breast cancer
Yotsumoto, F., Oki, E., Tokunaga, E., Maehara, Y., Kuroki, M., & Miyamoto, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25472 · Cited by 48
Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer
Farrugia, M. K., Sharma, S. B., Lin, C.-C., McLaughlin, S. L., Vanderbilt, D. B., Ammer, A. G., Salkeni, M. A., Stoilov, P., Agazie, Y. M., Creighton, C. J., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.65 · Cited by 49
Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer
Rowe, D. L., Ozbay, T., Bender, L. M., & Nahta, R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0012 · Cited by 48
Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer.
Ayyappan, S. R., Prabhakar, D., & Sharma, N. (2013) · PubMed · Cited by 48
Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer
Sun, L., Burnett, J., Gasparyan, M., Xu, F., Jiang, H., Lin, C.-C. A., Myers, I., Körkaya, H., Liu, Y., Connarn, J. N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9839 · Cited by 49
Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
Malm, M., Frejd, F. Y., Ståhl, S., & Löfblom, J. (2016) · mAbs · doi:10.1080/19420862.2016.1212147 · Cited by 52
Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines.
Zazo, S., Gónzález-Alonso, P., Martı́n-Aparicio, E., Chamizo, C., Cristóbal, I., Arpí, O., Rovira, A., Albanell, J., Eroles, P., Lluch, A. M., et al. (2016) · PubMed Central · Cited by 48
Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer
Takada, K., Kashiwagi, S., Goto, W., Asano, Y., Takahashi, K., Takashima, T., Tomita, S., Ohsawa, M., Hirakawa, K., & Ohira, M. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1460-4 · Cited by 48
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer
Ligorio, F., Pellegrini, I., Castagnoli, L., Vingiani, A., Lobefaro, R., Zattarin, E., Santamaria, M., Pupa, S. M., Pruneri, G., de Braud, F., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.023 · Cited by 49
The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection
Vasilcanu, D., Weng, W.-H., Girnita, A., Lui, W., Vasilcanu, R., Axelson, M., Larsson, O. S., Larsson, C., & Girnita, L. (2005) · Oncogene · doi:10.1038/sj.onc.1209339 · Cited by 48
Prognostic Factors in Metastatic Breast Cancer: Successes and Challenges Toward Individualized Therapy
Andreopoulou, E., & Hortobágyi, G. N. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1026 · Cited by 48
IQGAP1 Protein Binds Human Epidermal Growth Factor Receptor 2 (HER2) and Modulates Trastuzumab Resistance
White, C. D., Li, Z., Dillon, D. A. R., & Sacks, D. B. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.220939 · Cited by 47
Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
Park, Y. H., Jung, H. A., Choi, M. K., Chang, W., Choi, Y., Do, I.-G., Ahn, J. S., & Im, Y.-H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.757 · Cited by 47
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer
Vu, T., Sliwkowski, M. X., & Claret, F. X. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.007 · Cited by 47
PI3 Kinase Activation and Response to Trastuzumab Therapy: What's neu with Herceptin Resistance?
Park, B. H., & Davidson, N. E. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.004 · Cited by 47
HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance
Huang, X., Wang, S., Lee, C., Yang, X., & Liu, B. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.03.019 · Cited by 47
Arsenic trioxide decreases AKT protein in a caspase-dependent manner
Mann, K. K., Colombo, M., & Miller, W. H. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2164 · Cited by 47
Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient
Hirotsu, Y., Nakagomi, H., Amemiya, K., Oyama, T., Inoue, M., Mochizuki, H., & Omata, M. (2016) · Medical Oncology · doi:10.1007/s12032-016-0857-2 · Cited by 47
PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
Kim, C., Lee, C., Chon, H. J., Kim, J. H., Park, H. S., Heo, S. J., Kim, H. J., Kim, T. S., Kwon, W. S., Chung, H. C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23054 · Cited by 47
The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-βSignaling in Breast Cancer Malignancy
Wang, S. E. (2011) · Journal of Signal Transduction · doi:10.1155/2011/804236 · Cited by 49
Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer Cells
Belkhiri, A., Dar, A. A., Peng, D., Razvi, M. H., Rinehart, C., Arteaga, C. L., & El-Rifai, W. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0121 · Cited by 47
Pan-cancer genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome
Vidotto, T., Melo, C. M., Lautert-Dutra, W., Chaves, L. P., dos Reis, R. B., & Squire, J. A. (2023) · Scientific Reports · doi:10.1038/s41598-023-31759-6 · Cited by 47
mTOR inhibitors in the treatment of breast cancer.
Vinayak, S., & Carlson, R. W. (2013) · PubMed · Cited by 46
HER2 Silences Tumor Suppression in Breast Cancer Cells by Switching Expression of C/EBPβ Isoforms
Estape, A. A., Tarragona, M., Morales, M. L. G., Guiu, M., Nadal, C., Massagué, J., & Gomis, R. R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0869 · Cited by 46
Cooperative Effects of Akt-1 and Raf-1 on the Induction of Cellular Senescence in Doxorubicin or Tamoxifen Treated Breast Cancer Cells
Taylor, J. R., Lehmann, B. D., Chappell, W. H., Abrams, S. L., Steelman, L. S., & McCubrey, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.315 · Cited by 46
PIK3CAH1047R and Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling
Cheng, H.-L., Liu, P.-X., Ohlson, C. E., Xu, E., Symonds, L., Isabella, A., Muller, W., Lin, N., Krop, I., Roberts, T., et al. (2015) · Oncogene · doi:10.1038/onc.2015.377 · Cited by 40
PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers
Wang, Q., Liu, P., Spangle, J. M., Von, T., Roberts, T. M., Lin, N., Krop, I. E., Winer, E. P., & Zhao, J. J. (2015) · Oncogene · doi:10.1038/onc.2015.406 · Cited by 46
Associations of ErbB2, β1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines
Mocanu, M., Fazekas, Z., Petrás, M., Nagy, P., Sebestyén, Z., Isola, J. J., Tı́már, J., Park, J. W., Vereb, G., & Szöllõsi, J. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.028 · Cited by 46
Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer
Kim, C. G., Jung, M., Kim, H. S., Lee, C., Jeung, H., Koo, D., Bae, W. K., Zang, D. Y., Kim, B. J., Kim, H., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02122 · Cited by 46
The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances
Khorasani, A. B. S., Hafezi, N., Sanaei, M., Jafari‐Raddani, F., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3998 · Cited by 47
The role of targeted therapy and biomarkers in breast cancer treatment
Stopeck, A., Brown-Glaberman, U. A., Wong, H. Y., Park, B. H., Barnato, S. E., Gradishar, W. J., Hudis, C. A., & Rugo, H. S. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9496-y · Cited by 46
Partial PTEN deletion is linked to poor prognosis in breast cancer
Lebok, P., Kopperschmidt, V., Kluth, M., Hube‐Magg, C., Özden, C., Taskin, B., Hussein, K. R., Mittenzwei, A., Lebeau, A., Witzel, I., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1770-3 · Cited by 45

Authors: Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., Hortobagyi, G. N., Hung, M.-C., & Yu, D.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Ionis Pharmaceuticals (United States) (US)
Corresponding author: Yu, Dihua
ORCID: Lan, Keng-Hsueh
Zhou, Xiaoyan
Tan, Ming
Esteva, Francisco J.
Li, Ping
Monia, Brett P.
Hung, Mien-Chie
Yu, Dihua
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2004-08
Volume: 6
Issue: 2
Pages: 117-127
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2004.06.022
OpenAlex: W2059411043
Cited by: 1,858
References: 70
Citations by year: 2026: 19 · 2025: 29 · 2024: 35 · 2023: 82 · 2022: 52 · 2021: 50 · 2020: 60 · 2019: 56 · 2018: 66 · 2017: 68 · 2016: 88 · 2015: 109 · 2014: 119 · 2013: 125 · 2012: 123
FWCI: 43.34
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3272 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ca060488-09)
National Cancer Institute (P01CA099031, 2R01-CA60488, P30CA016672)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: PTEN, trastuzumab, trastuzumab resistance, ERBB2, HER2-positive breast cancer, Src kinase inhibition, PI3K inhibitors, predictive biomarkers, antisense oligonucleotides
MeSH terms: Trastuzumab, Phosphoinositide-3 Kinase Inhibitors, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Enzyme Activation, Enzyme Inhibitors, Female, Humans, Mice, Nude, Neoplasm Transplantation, Phosphoric Monoester Hydrolases, Proto-Oncogene Proteins, Genes, Tumor Suppressor, Oligonucleotides, Antisense, Protein Serine-Threonine Kinases, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, src-Family Kinases, Phosphatidylinositol 3-Kinases, Tumor Suppressor Proteins, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Mice, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks